Income Taxes |
9 Months Ended |
|---|---|
Oct. 31, 2022 | |
| Income Tax Disclosure [Abstract] | |
| Income Taxes | Income Taxes The Company recognized income tax expense of $8.9 million and $4.5 million for the three months ended October 31, 2022 and October 31, 2021, respectively, and $17.1 million and $58.8 million for the nine months ended October 31, 2022 and October 31, 2021, respectively. The tax expense for the three and nine months ended October 31, 2022 was primarily attributable to the tax impact from the intercompany sale of intellectual property, pre-tax foreign earnings and withholding taxes related to customer payments in certain foreign jurisdictions in which the Company conducts business. The tax expense for the three months ended October 31, 2021 was primarily attributable to pre-tax foreign earnings. The tax expense for the nine months ended October 31, 2021 was primarily attributable to the intercompany sale of intellectual property from Humio and pre-tax foreign earnings. The Company’s effective tax rates of (19.4)% and (9.7)% for the three months ended October 31, 2022 and October 31, 2021, respectively, differ from the U.S. statutory tax rate primarily due to U.S. losses for which there is no benefit and the tax impact from the intercompany sale of intellectual property for the three months ended October 31, 2022. The Company’s effective tax rates of (14.7)% and (43.8)% for the nine months ended October 31, 2022 and October 31, 2021, respectively, differ from the U.S. statutory tax rate primarily due to U.S. losses for which there is no benefit, the tax impact from the intercompany sale of intellectual property from acquisitions for the nine months ended October 31, 2022, and October 31, 2021, respectively. The Company has a full valuation allowance on its U.S. federal and state and its U.K. deferred tax assets. As a result, the Company does not record a tax benefit on these losses because it is more likely than not that the benefit will not be realized. The balance of gross unrecognized tax benefits was $37.3 million and $26.3 million as of October 31, 2022 and January 31, 2022, respectively. The increase was primarily due to establishing an uncertain tax position associated with research & development tax credits. As of October 31, 2022 and January 31, 2022, approximately $4.7 million and $1.9 million, respectively of the unrecognized tax benefits including interest and penalties would affect the Company’s effective tax rate if favorably resolved. The Company is subject to examination by tax authorities both domestically and internationally. The Company believes that adequate amounts have been reserved for any adjustments that may result from these examinations, although the Company cannot assure that this will be the case given the inherent uncertainties in these examinations. It is impractical to determine the amount and timing of these adjustments. The potential change in unrecognized tax benefits during the next 12 months is not expected to be material. In accordance with the guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax jurisdictions, the Company recognizes potential liabilities for anticipated tax audit issues based on the Company’s estimate of whether, and the extent to which, additional taxes and interest will be due. If the Company’s estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events occur and the payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when the Company determines the liabilities are no longer necessary. The Company includes interest and penalties related to unrecognized tax benefits within the provision for income taxes in the condensed consolidated statements of operations. Accrued interest and penalties are included within other liabilities, noncurrent on the condensed consolidated balance sheet.
|